 |
|
Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience
Hong Joo Kim, Yong Kyun Cho, Woo Kyu Jeon, Byung Ik Kim
Clin Mol Hepatol. 2017;23(4):323-330. Published online 2017 Sep 5 DOI: https://doi.org/10.3350/cmh.2017.0005
|
|
Citations to this article as recorded by
 The association of the heterogeneity of HBV reverse transcriptase quasispecies with antiviral efficacy after treatment with nucleos(t)ide analogues for 10 years
Tai-Cheng Zhou, Feng-Wei Liu, Jing-Hua Fan, Si-Hang Zhang, Song-Qin Lv, Zhi-Yong Yu, Yan-Mei Zhang, Liang Zhang, Jia Wei
Infection, Genetics and Evolution.2021; 89: 104706. CrossRef Detection of Hepatitis B Virus M204V Mutation Quantitatively via Real-time PCR
Jingjing Liang, Xinmiao Liang, Hong Ma, Leng Nie, Ying Tian, Guang Chen, Yu Wang
Journal of Clinical and Translational Hepatology.2021; 000(000): 000. CrossRef Hepatitis B virus resistance to tenofovir: fact or fiction? A systematic literature review and structural analysis of drug resistance mechanisms
Jolynne Mokaya, Anna L. McNaughton, Phillip A Bester, Dominique Goedhals, Eleanor Barnes, Brian D Marsden, Philippa C. Matthews
Wellcome Open Research.2020; 5: 151. CrossRef Current state-of-the-art pharmacotherapy for the management of hepatitis B infection
Hans L. Tillmann, Gbeminiyi Samuel
Expert Opinion on Pharmacotherapy.2019; 20(7): 873. CrossRef Entecavir
Reactions Weekly.2018; 1688(1): 98. CrossRef Is it possible to predict the development of an entecavir resistance mutation in patients with chronic hepatitis B in clinical practice?
Joon Yeul Nam, Jeong-Hoon Lee
Clinical and Molecular Hepatology.2017; 23(4): 311. CrossRef
|